SCYNEXIS Announces FDA Acceptance and Priority Review of New Drug Application for Oral Ibrexafungerp for the Treatment of Vaginal Yeast InfectionsGlobeNewsWire • 12/07/20
SCYNEXIS Reports Third Quarter 2020 Financial Results and Provides Company UpdateGlobeNewsWire • 11/06/20
SCYNEXIS to Present Data Supporting the Efficacy of Ibrexafungerp Against Invasive Fungal Infections at IDWeek 2020GlobeNewsWire • 10/21/20
SCYNEXIS Announces Submission of New Drug Application to the U.S. Food and Drug Administration for Oral Ibrexafungerp for the Treatment of Vaginal Yeast InfectionGlobeNewsWire • 10/14/20
SCYNEXIS to Present Two Posters Highlighting Ibrexafungerp for the Treatment of Vaginal Yeast Infection at the 23rd Annual Premier Women's Healthcare Virtual ConferenceGlobeNewsWire • 10/12/20
SCYNEXIS to Participate in H.C. Wainwright Conference and Maxim’s Antifungal WebinarGlobeNewsWire • 09/10/20
SCYNEXIS Announces Presentations at 2020 IDSOG Virtual Annual Meeting Highlighting Ibrexafungerp’s Potential for the Treatment of Vulvovaginal CandidiasisGlobeNewsWire • 08/13/20
SCYNEXIS Reports Second Quarter 2020 Financial Results and Provides Company UpdateGlobeNewsWire • 08/10/20
SCYNEXIS Reports Successful Completion of Pre-NDA Meetings with the FDA Regarding Ibrexafungerp for the Treatment of Vulvovaginal CandidiasisGlobeNewsWire • 07/29/20
SCYNEXIS Announces Four Posters Presented at ASM Microbe 2020 Highlighting the Potential Clinical Utility of IbrexafungerpGlobeNewsWire • 07/22/20
SCYNEXIS to Host A Key Opinion Leader Discussion on the Immediate Need in Treating Women with Vaginal Yeast InfectionsGlobeNewsWire • 07/09/20
SCYNEXIS Strengthens Leadership Team with Appointment of Jim Maffezzoli as Vice President of Marketing and SalesGlobeNewsWire • 06/02/20
SCYNEXIS Reports First Quarter 2020 Financial Results and Provides Company UpdateGlobeNewsWire • 05/11/20
SCYNEXIS Announces Six Abstracts Published by 30th ECCMID Highlighting the Potential Clinical Utility of IbrexafungerpGlobeNewsWire • 05/06/20
SCYNEXIS Announces Positive Top-Line Results from its Second Pivotal Phase 3 Study (VANISH-306) of Oral Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis (Vaginal Yeast Infection)GlobeNewsWire • 04/21/20
SCYNEXIS and Aspire Capital Enter into $20 Million Common Stock Purchase AgreementGlobeNewsWire • 04/13/20
SCYNEXIS Secures $10 Million in Financing through Senior Convertible Note Purchase Agreement with Puissance CapitalGlobeNewsWire • 04/09/20
Analysts Estimate Scynexis (SCYX) to Report a Decline in Earnings: What to Look Out forZacks Investment Research • 11/05/19